Intravenous Allopurinol in Heart Failure
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure|
- Myocardial Creatine Kinase (CK) Flux Pre Intravenous Allopurinol Infusion [ Time Frame: Onset of imaging acquisition. ]Magnetic resonance spectroscopy (MRS) Measurement of Myocardial CK Flux Pre Intravenous Allopurinol Infusion
- Myocardial CK Flux Post Intravenous Allopurinol Infusion. [ Time Frame: acute (within 15 minutes of single infusion) ]The mean rate of adenosine triphosphate (ATP) flux through the creatine kinase reaction in the heart.
- Cardiac PCr/ATP Pre Intravenous Infusion [ Time Frame: Onset of image acquisition. ]The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.
- Cardiac PCr/ATP Post Intravenous Infusion [ Time Frame: acute (within 15 minutes of single infusion) ]The mean ratio of creatine phosphate (PCr) to ATP in the heart. This measure, as a ratio, is unitless.
|Study Start Date:||November 2004|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
intravenous infusion of allopurinol (300mg)
Other Name: Aloprim
Placebo Comparator: Placebo
One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
intravenous infusion of 50 ml dose of 5% dextrose
Other Name: 5% Dextrose
Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts. The investigators developed a means to directly measure creatine kinase flux, the major energy reserve of the heart, in the human heart exploiting new magnetic resonance technologies.
The investigators propose to study 10 healthy subjects and up to 25 with heart failure (dilated cardiomyopathy) before and after a single 300mg IV infusion of allopurinol.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00181155
|United States, Maryland|
|Johns Hopkins Hospital|
|Baltimore, Maryland, United States, 21287|
|Principal Investigator:||Robert G Weiss, MD||Johns Hopkins University|